Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.neclife.com | |
Market Cap | 648.79 Cr. | |
Enterprise Value(EV) | 1,331.18 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -0.12 | Trailing Twelve Months Ending 2023-09 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-09 |
Industry PE | 38.33 | Trailing Twelve Months Ending 2023-09 |
Book Value / Share | 47.60 | Trailing Twelve Months Ending 2023-09 |
Price to Book Value | 0.61 | Calculated using Price: 28.93 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 22.43 Cr. | 224,260,970 Shares |
FaceValue | 1 | |
About Nectar Lifesciences Ltd. | ||
Nectar Lifesciences (NecLife) incorporated in 1995, is a $200 million pharmaceutical organization. The company offers a range of Cephalosporin active pharmaceutical ingredients (APIs) and finished dosage forms. The company was previously known as Surya Medicare and is is promoted by Sanjiv Goyal. |
1 Day |
|
-0.45% |
1 Week |
|
-2.03% |
1 Month |
|
+18.04% |
3 Month |
|
+6.82% |
6 Month |
|
+63.18% |
1 Year |
|
+29.09% |
2 Year |
|
+15.92% |
5 Year |
|
+47.86% |
10 Year |
|
+76.17% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 7.17 | 5.78 | 5.64 | 5.06 | 4.40 | 2.84 | -6.67 | 2.33 | -2.25 | |
Return on Capital Employed (%) | 11.58 | 9.95 | 9.73 | 9.13 | 10.29 | 8.32 | 1.41 | 5.77 | 1.97 | |
Return on Assets (%) | 2.70 | 2.14 | 2.15 | 1.97 | 1.75 | 1.19 | -2.93 | 1.05 | -1.06 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 958 | 954 | 1,007 | 1,059 | 1,105 | 1,136 | 1,062 | 1,088 | 1,065 | 1,067 | |
Non Curr. Liab. | 397 | 362 | 296 | 356 | 300 | 249 | 126 | 296 | 213 | 172 | |
Curr. Liab. | 1,156 | 1,240 | 1,279 | 1,309 | 1,300 | 1,248 | 1,187 | 1,004 | 891 | 885 | |
Minority Int. | |||||||||||
Equity & Liab. | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,376 | 2,388 | 2,169 | 2,124 | |
Non Curr. Assets | 1,106 | 1,092 | 1,085 | 1,063 | 1,036 | 1,018 | 1,137 | 1,033 | 937 | 916 | |
Curr. Assets | 1,369 | 1,464 | 1,496 | 1,661 | 1,669 | 1,615 | 1,239 | 1,355 | 1,231 | 1,208 | |
Misc. Exp. not W/O | 36 | ||||||||||
Total Assets | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,376 | 2,388 | 2,169 | 2,124 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09 Rs. Cr. TTM |
Net Sales | 1,644 | 1,676 | 1,644 | 1,876 | 2,783 | 2,366 | 1,543 | 1,669 | 1,524 | 1,525 | |
Other Income | 20 | 6 | 23 | 6 | 6 | 4 | 11 | 11 | 43 | 42 | |
Total Income | 1,664 | 1,681 | 1,666 | 1,882 | 2,789 | 2,371 | 1,555 | 1,680 | 1,567 | 1,567 | |
Total Expenditure | -1,377 | -1,437 | -1,419 | -1,640 | -2,519 | -2,147 | -1,442 | -1,510 | -1,471 | -1,443 | |
PBIDT | 287 | 245 | 247 | 242 | 270 | 224 | 113 | 170 | 96 | 124 | |
Interest | -126 | -123 | -117 | -115 | -148 | -126 | -112 | -79 | -79 | -75 | |
Depreciation | -77 | -57 | -62 | -64 | -63 | -61 | -60 | -57 | -59 | -60 | |
Taxation | -18 | -10 | -12 | -10 | -11 | -6 | 12 | -9 | 18 | 9 | |
Exceptional Items | -25 | ||||||||||
PAT | 66 | 54 | 55 | 52 | 48 | 32 | -73 | 25 | -24 | -3 | |
Minority Interest | |||||||||||
Share Associate | |||||||||||
Other Related Items | 1 | ||||||||||
Consolidated Net Profit | 66 | 54 | 55 | 52 | 48 | 32 | -73 | 25 | -24 | -3 | |
Adjusted EPS | 3 | 2 | 2 | 2 | 2 | 1 | -3 | 1 | -1 | 0 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 255 | 144 | 169 | 199 | 65 | 239 | 285 | 21 | 95 | 134 | |
Cash Fr. Inv. | -90 | -60 | -77 | -18 | -29 | -26 | -33 | -29 | 17 | 52 | |
Cash Fr. Finan. | -161 | -61 | -89 | -204 | -40 | -201 | -252 | 11 | -119 | -186 | |
Net Change | 4 | 23 | 3 | -23 | -4 | 12 | 0 | 4 | -8 | 0 | |
Cash & Cash Eqvt | 10 | 33 | 37 | 13 | 9 | 21 | 21 | 26 | 18 | 18 |
Sat, 11 Nov 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication Please find attached herewith the copy of newspapers for publication of financial results for the period ended on 30.09.2023 |
Fri, 10 Nov 2023
Unaudited Financial Results For The Period Ended On 30.09.2023 Please find attached herewith Unaudited Financial Results for the period ended on September 30 2023. |
Fri, 03 Nov 2023
Board Meeting Intimation for Board Meeting Intimation For Financial Results For The Quarter And Half Year Ended On September 30 2023 And Other Business Matters. NECTAR LIFESCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 inter alia to consider and approve the financial Results for the quarter and half year ended on September 30 2023 and other business matters. |
Mon, 11 Dec 2023 |
|
|
|
|
|